{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tawara M"],"funding":["the Japan Agency for Medical Research and Development","Japan Society for the Promotion of Science"],"pagination":["9170"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12470293"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(18)"],"pubmed_abstract":["CD44 variants (CD44v) play essential roles in the promotion of tumor metastasis, maintenance of cancer stem cell properties, and resistance to treatments. Therefore, the development of anti-CD44v mAbs is essential for targeting CD44v-positive tumor cells. An anti-CD44v9 mAb, C<sub>44</sub>Mab-1 (mouse, IgG<sub>1</sub>, kappa), was previously established. C<sub>44</sub>Mab-1 recognizes the variant exon 9-encoded region and applies to multiple research techniques. A mouse IgG<sub>2a</sub> version of C<sub>44</sub>Mab-1 (C<sub>44</sub>Mab-1-mG<sub>2a</sub>) was generated to evaluate the in vitro and in vivo antitumor activities using gastric and colorectal cancer cell lines. C<sub>44</sub>Mab-1-mG<sub>2a</sub> showed a reactivity to CD44v3-10-overexpressed Chinese hamster ovary-K1 (CHO/CD44v3-10), gastric cancer MKN45, and colorectal cancer COLO205 in flow cytometry. C<sub>44</sub>Mab-1-mG<sub>2a</sub> exhibited both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CHO/CD44v3-10, MKN45, and COLO205. Furthermore, administration of C<sub>44</sub>Mab-1-mG<sub>2a</sub> significantly suppressed CHO/CD44v3-10, MKN45, and COLO205 xenograft tumor growth compared with control mouse IgG<sub>2a</sub>. These results indicated that C<sub>44</sub>Mab-1-mG<sub>2a</sub>, which possesses ADCC/CDC activities, could be applied to the mAb-based therapy against CD44v9-positive carcinomas."],"journal":["International journal of molecular sciences"],"pubmed_title":["Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models."],"pmcid":["PMC12470293"],"funding_grant_id":["25K10553 (to Y.K.)","JP25am0521010 (to Y.K.), JP25ama121008 (to Y.K.), JP25ama221339 (to Y.K.), and JP25bm1123027 (to Y.K.)"],"pubmed_authors":["Kaneko MK","Kato Y","Tawara M","Suzuki H","Ohishi T"],"additional_accession":[]},"is_claimable":false,"name":"Antitumor Activity by an Anti-CD44 Variant 9 Monoclonal Antibody in Gastric and Colorectal Cancer Xenograft Models.","description":"CD44 variants (CD44v) play essential roles in the promotion of tumor metastasis, maintenance of cancer stem cell properties, and resistance to treatments. Therefore, the development of anti-CD44v mAbs is essential for targeting CD44v-positive tumor cells. An anti-CD44v9 mAb, C<sub>44</sub>Mab-1 (mouse, IgG<sub>1</sub>, kappa), was previously established. C<sub>44</sub>Mab-1 recognizes the variant exon 9-encoded region and applies to multiple research techniques. A mouse IgG<sub>2a</sub> version of C<sub>44</sub>Mab-1 (C<sub>44</sub>Mab-1-mG<sub>2a</sub>) was generated to evaluate the in vitro and in vivo antitumor activities using gastric and colorectal cancer cell lines. C<sub>44</sub>Mab-1-mG<sub>2a</sub> showed a reactivity to CD44v3-10-overexpressed Chinese hamster ovary-K1 (CHO/CD44v3-10), gastric cancer MKN45, and colorectal cancer COLO205 in flow cytometry. C<sub>44</sub>Mab-1-mG<sub>2a</sub> exhibited both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CHO/CD44v3-10, MKN45, and COLO205. Furthermore, administration of C<sub>44</sub>Mab-1-mG<sub>2a</sub> significantly suppressed CHO/CD44v3-10, MKN45, and COLO205 xenograft tumor growth compared with control mouse IgG<sub>2a</sub>. These results indicated that C<sub>44</sub>Mab-1-mG<sub>2a</sub>, which possesses ADCC/CDC activities, could be applied to the mAb-based therapy against CD44v9-positive carcinomas.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-05-03T03:16:59.015Z","creation":"2026-05-03T03:11:29.769Z"},"accession":"S-EPMC12470293","cross_references":{"pubmed":["41009730"],"doi":["10.3390/ijms26189170"]}}